1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Publikationen

  • Fassl A, Tagscherer KE, Richter J, Berriel Diaz M, Alcantara Llaguno SR, Campos B, Kopitz J, Herold-Mende C, Herzig S, Schmidt MH, Parada LF, Wiestler OD, Roth W. Notch1 signaling promotes survival of glioblastoma cell via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene, in press.
  • Tagscherer KE, Fassl A, Sinkovic T, Combs SE, Roth W. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737. Apoptosis, in press
  • Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher S, Aulmann S. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Modern Pathology, in press
  • Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, Huber J, Zogal P, Teber D, Pahernik S, Roethke M, Zamecnik P, Roth W, Sakas G, Schlemmer HP, Hohenfellner M. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. The Journal of Urology, 186, 2214-20, 2011.
  • Roth W, Macher-Goeppinger S, Schirmacher P. Pathology and molecular pathogenesis of renal cell carcinoma. Nephrologe, in press.
  • Gdynia G, Roth W. Neue Aspekte der Regulation von Zelltod in Tumoren. Biospektrum, in press Macher-Goeppinger S, Roth W, Wagener N, Penzel R, Haferkamp A, Schirmacher P, Aulmann S. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Modern Pathology, in press
  • Funke B, Lasitschka F, Roth W, Penzel R, Meuer S, Saile M, Gretz N, Sido B, Schirmacher P, Autschbach F. Selective downregulation of retinoic acid-inducible gene I within the intestinal epithelial compartment in crohn's disease. Inflammatory Bowel Diseases 17, 1943-54, 2011
  • Metzig M, Nickles D, Falschlehner C, Lehmann-Koch J, Straub BK, Roth W, Boutros M. An RNAi screen identifies USP2 as a factor required for TNF-α induced NF-κB signaling. International Journal of Cancer 129, 607-18, 2011
  • Macher-Goeppinger S, Penzel R, Roth W, Dienemann H, Thomas M, Schnabel PA, Schirmacher P, Bläker H. Expression and mutation analysis of EGFR, c-KIT, and {beta}-catenin in pulmonary blastoma. Journal of Clinical Patholoy 64, 349-53, 2011
  • Gdynia G, Schnitzler P, Brunner E, Kandolf R, Bläker H, Daum E, Schnabel P, Schirmacher P, Roth, W. Sudden death of an immunocompetent young adult caused by novel (swine origin) influenza A/H1N1-associated myocarditis. Virchows Archiv 458, 371-76, 2011
  • Macher-Goeppinger S, Bermejo JL, Wagener N, Hohenfellner M, Haferkamp A, Schirmacher P, Roth W. Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Letters 301, 203-11, 2011
  • Gdynia G, Keith M, Kopitz J, Bergmann M, Fassl A, Weber ANR, George J, Kees T, Zentgraf HW, Wiestler OD, Schirmacher P, Roth W. Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Research 70, 8558-68, 2010
  • Böck BC, Tagscherer KE, Fassl A, Krämer A, Oehme I, Zentgraf HW, Keith M, Roth W. The PEA-15 protein regulates autophagy via activation of JNK. The Journal of Biological Chemistry 285, 21644-54, 2010
  • Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts V, Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clinical Cancer Research 16, 2715-28, 2010
  • Roth W. Tumorpathologie und Zelltod: Regulation der Apoptose in malignen Tumoren. Onkologie heute 1, 10-13, 2010
  • Michel S, Kloor M, Singh S, Gdynia G, Roth W, von Knebel Doeberitz M, Schirmacher P, Bläker H. Coding microsatellite instability analysis in microsatellite unstable small intestinal adenocarcinomas identifies MARCKS as a common target of inactivation. Molecular Carcinogenesis 49, 175-82, 2010
  • Roth W. Apoptosis resistance in malignant tumors: Novel apoptosis-based therapeutic approaches. Pathologe 30 Suppl 2, 113-6, 2009
  • Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, Gdynia G, Li L, Gretz N, Macher-Goeppinger S, Sido B, Schirmacher P, Meuer S, Roth W. Functional characterization of Decoy Receptor 3 in Crohn’s disease. Gut 58, 483-91, 2009
  • Macher-Goeppinger S, Aulmann S, Tagscherer KE, Wagener N, Haferkamp A, Penzel R, Brauckhoff A, Hohenfellner M, Sykora J, Walczak H, Teh BT, Autschbach F, Herpel E, Schirmacher P, Roth W. Prognostic value of Tumor Necrosis Factor-Related Apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clinical Cancer Research 15, 650-9, 2009
  • Grund K, Ahmadi R, Jung F, Funke V, Gdynia G, Benner A, Sykora J, Walczak H, Joos S, Felsberg J, Reifenberger G, Wiestler OD, Herold-Mende C, Roth W. Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biology & Therapy 7, 1982-90, 2008
  • Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene, 27, 6646-56, 2008
  • Macher-Goeppinger S, Aulmann S, Wagener N, Funke N, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W. Decoy Receptor 3 is a prognostic factor in renal cell cancer. Neoplasia, 10, 1049-56, 2008
  • Koch A, Roth W, Steffek TM, Dengler TJ, Haass M, Karck M, Sack FU, Schirmacher P, Schnabel PA. Impact of apoptosis in acute rejection episodes after heart transplantation: immunohistochemical examination of right ventricular myocardial biopsies. Transplantation Proceedings 40, 943-6, 2008
  • Fassl A, Tagscherer KE, Herold-Mende C, Wiestler OD, Roth W. Apoptosis resistance in glioblastoma stem cells – a question of Notch? AACR-AstraZeneca International Scholar-in-Training Award (The Role of Cancer Stem Cells in the Initiation and Propagation of Tumorigenesis, Los Angeles, 2008)
  • Gdynia G, Lehmann J, Sieber S, Tagscherer KE, Fassl A, Zentgraf H, Matsuzawa S, Reed JC, Roth W. BLOC1S2 interacts with the HIPPI protein and sensitizes NCH89 glioblastoma cells to apoptosis. Apoptosis 13, 437-47, 2008
  • Gdynia G, Grund K, Eckert A, Böck BC, Funke B, Macher-Göppinger S, Sieber S, Herold-Mende C, Wiestler B, Wiestler OD, Roth W. Basal caspase activity promotes migration and invasiveness in glioblastoma cells. Molecular Cancer Research 5, 1232-40, 2007
  • Eckert A*, Böck B*, Tagscherer KE, Haas TL, Grund K, Sykora J, Herold-Mende C, Ehemann V, Hollstein M , Chneiweiss H, Wiestler OD, Walczak H, Roth W. The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway. Oncogene 27 1155-66, 2008(* shared first authorship)
  • Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. International Journal of Radiation Oncology, Biology, Physics 68, 873-82, 2007
  • Gassler N *, Roth W *, Funke B, Schneider A, Herzog F, Tischendorf JJW, Grund K, Penzel R, Bravo IG, Mariadason J, Ehemann V, Sykora J, Haas TL, Walczak H, Ganten T, Zentgraf H, Erb P, Alonso A, Autschbach F, Schirmacher P, Knüchel R, Kopitz J Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology 133, 587-598, 2007(* shared first authorship)
  • Eckert A, Kloor M, Giersch A, Ahmadi R, Herold-Mende C, Hampl JA, Heppner FL, Zoubaa S, Holinski-Feder E, Pietsch T, Wiestler O, von Knebel Doeberitz M, Roth W, Gebert J. Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathology 17, 146-50, 2007
  • Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, Roth W, Friess H, Schirmacher P. cIAP2 Overexpression is an early event in pancreatic cancer progression. Journal of Clinical Pathology 60, 885-95, 2007
  • Schultze K, Böck B, Eckert A, Oevermann L, Ramacher D, Wiestler O, Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11, 1503-12, 2006
  • Roth W, Bucsenez D, Bläker H, Berger I, Schnabel P. Misalignment of pulmonary vessels with alveolar capillary dysplasia: Association with atrioventricular septal defect and quadricuspid pulmonary valve. Virchows Archiv 448, 375-378, 2006 Roth, W, Reed, JC. FLIP protein and TRAIL-induced apoptosis. Vitamins and Hormones 67, 189-206, 2004
  • Tong X, Xie D, Roth W, Reed J, Koeffler HP. NADE (p75NTR-associated cell death executor) suppresses cellular growth in vivo. International Journal of Oncology 22, 1357-62, 2003
  • Roth W, Kermer P, Krajewska M, Welsh K, Davis S, Krajewski S, Reed JC. Bifunctional apoptosis inhibitor (BAR) protects neurons from diverse cell death pathways. Cell Death and Differentiation 10, 1178-87, 2003
  • Reed JC, Doctor K, Rojas A, Zapata JM, Stehlik C, Fiorentino L, Damiano J, Roth W, Matsuzawa S, Newman R, Takayama S, Marusawa H, Xu F, Salvesen G, Godzik A. Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Research, 13, 1376-88, 2003
  • Weller M, Wick W, Steinbach J, Wagenknecht B, Naumann U, Roth W. The role of apoptosis in cancerogenesis and resistance to therapy: lessons from malignant glioma. In: Zierhut M, Jager, M, Ksander, B, ed. Immunology of Ocular Tumors. Sassenheim, Netherlands: Swets & Zeitlinger Publishers; 131-139, 2002
  • Roth W, Reed JC. Apoptosis and cancer: when BAX is TRAILing away. Nature Medicine 8, 216-8, 2002
  • Roth W, Stenner-Liewen F, Pawlowski K, Godzik A, Reed JC. Identification and characterization of DEDD2, a death effector domain-containing protein. Journal of Biological Chemistry 277, 7501-8, 2002
  • Wagenknecht B, Roth W, Gulbins E, Wolburg H, Weller M. C2-ceramide signaling in glioma cells: synergistic enhancement of CD95-mediated, caspase-dependent apoptosis. Cell Death and Differentiation 8, 595-602, 2001
  • Roth W, Weller M. Death ligand/death receptor-mediated apoptosis in malignant glioma. In: Liau LM BD, Cloughsey TF, Bigner DD, ed. Brain Tumor Immunotherapy. Totowa, NJ, USA: Humana Press; 327-344, 2001
  • Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death and Differentiation 8, 403-10, 2001
  • Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Research 61, 2759-65, 2001
  • Rohn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20, 4128-37, 2001
  • Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, Weller M. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 19, 4210-20, 2000
  • Roth W, Grimmel C, Rieger L, Strik H, Takayama S, Krajewski S, Dichgans J, Reed JC, Weller M. Bag-1 and Bcl-2 gene transfer in malignant glioma: Modulation of cell cycle regulation and apoptosis. Brain Pathology 10, 223-234, 2000
  • Roth W, Bähr M, Weller M. Death ligands/death receptors (CD95/DR4/5): new weapons against malignant glioma. Neuroforum 3, 87-92, 1999
  • Roth W, Weller M. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cellular and Molecular Life Sciences 56, 481-506, 1999
  • Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A, Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochemical and Biophysical Research Communications 265, 479-483, 1999
  • Rieger J, Roth W, Glaser T, Winter S, Rieger L, Dichgans J, Weller M. Glioblastoma multiforme: mechanisms of resistance to chemotherapy. Neurology Psychiatry and Brain Research 7, 47-50, 1999
  • Winter S, Roth W, Dichgans J, Weller M. Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression. European Journal of Pharmacology, 1998 Roth W. The CD95/CD95 ligand system - New approaches to the treatment of malignant brain tumors? Fortschritte der Medizin 116, 52-55, 1998
  • Roth W, Wagenknecht B, Dichgans J, Weller M. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells. Journal of Neuroimmunology 87, 121-9, 1998
  • Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells. Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. British Journal of Cancer 77, 404-411, 1998
  • Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. Journal of Immunology 159, 2108-2115, 1997
  • Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48, 1704-1709, 1997
  • Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M. Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunology, Immunotherapy 44, 55-63, 1997

Letzte Aktualisierung: 21.12.2011 Seitenanfang